These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9798483)

  • 1. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
    Goldstein F
    Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
    [No Abstract]   [Full Text] [Related]  

  • 2. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
    Lode H
    Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
    [No Abstract]   [Full Text] [Related]  

  • 3. [What pharmacodynamic elements affect Augmentin in man?].
    Jehl F
    Presse Med; 1998 Sep; 27 Suppl 4():20-1. PubMed ID: 9798482
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
    Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
    Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the pneumologist].
    Poirier R
    Presse Med; 1998 Sep; 27 Suppl 4():14-5. PubMed ID: 9798478
    [No Abstract]   [Full Text] [Related]  

  • 6. Doxycycline for treatment of community-acquired pneumonia.
    Johnson JR
    Clin Infect Dis; 2002 Sep; 35(5):632; author reply 632-3. PubMed ID: 12173142
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beta-lactamase producers and other bacteria: which ones to take into consideration and when? The viewpoint of the microbiologist].
    Quentin C
    Presse Med; 1998 Sep; 27 Suppl 4():12-3. PubMed ID: 9798477
    [No Abstract]   [Full Text] [Related]  

  • 10. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G; Berry V
    Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proof of concept: performance testing in models.
    Craig WA
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Data of experimental models].
    Bedos JP
    Presse Med; 1998 Sep; 27 Suppl 4():19-20. PubMed ID: 9798481
    [No Abstract]   [Full Text] [Related]  

  • 14. Amoxicillin-clavulanic acid: additions and corrections.
    Ackerman BH; Wynne B
    Mayo Clin Proc; 1999 Oct; 74(10):1050-1. PubMed ID: 10918874
    [No Abstract]   [Full Text] [Related]  

  • 15. The in-vitro activities of co-amoxiclav and other oral antibiotics against Streptococcus pneumoniae isolates exhibiting intermediate susceptibility to penicillin.
    Washington JA; Felmingham D
    J Antimicrob Chemother; 1998 Sep; 42(3):405-6. PubMed ID: 9786488
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia.
    Viasus D; Simonetti AF; Garcia-Vidal C; Niubó J; Dorca J; Carratalà J
    J Antimicrob Chemother; 2017 Feb; 72(2):547-553. PubMed ID: 27798219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of macrolide resistance in Streptococcus pneumoniae.
    Nuermberger EL; Bishai WR
    J Antimicrob Chemother; 2003 Sep; 52(3):524-5; author reply 525. PubMed ID: 12888594
    [No Abstract]   [Full Text] [Related]  

  • 19. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
    Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
    Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM; Prause JL; Danziger LH; Pendland SL
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.